News

Rothschild & Co Redburn initiated coverage of MoonLake Immunotherapeutics (MLTX) with a Neutral rating and $65 price target Published first on ...
When building your watch list, look for stocks with an 80 or higher RS Rating. MoonLake Immunotherap MLTX is one stock that ...
Sonelokimab (M1095) is an investigational ~40 kDa humanized Nanobody® consisting of three VHH domains covalently linked by flexible glycine-serine spacers. With two domains, sonelokimab ...
Short interest in MoonLake Immunotherapeutics (NASDAQ:MLTX) decreased during the last reporting period, falling from 6.10M to 6.04M. This put 21.36% of the company's publicly available shares short.
So, the natural question for MoonLake Immunotherapeutics (NASDAQ:MLTX) shareholders is whether they should be concerned by its rate of cash burn.For the purpose of this article, we'll define cash ...
MoonLake has recently announced the successful outcome of its end-of-Phase 2 interactions with the U.S. Food and Drug Administration (FDA) the E.U. European Medicines Agency (EMA), with both ...
MoonLake Immunotherapeutics (MLTX) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings ...
MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update. Continued to make significant progress with the development of the Nanobody ® sonelokimab ...
MoonLake Immunotherapeutics Media & Investors Relations . Carla Bretes, Director IR & External Communications. [email protected]. ICR Healthcare . Mary-Jane Elliott, Namrata Taak, Ashley Tapp.
New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent hidradenitis suppurativa (HS), Phase 2 LEDA trial in palmoplantar ...
MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11 Initiated Phase 3 VELA program of the Nanobody® sonelokimab in ...
MoonLake Immunotherapeutics (NASDAQ:MLTX) is a good speculative biotech play to look into.That's because it reported positive results from a phase 2 study using its drug sonelokimab for the ...